AIM ImmunoTech Inc. 8-K

What Happened
AIM ImmunoTech Inc. announced on May 20–21, 2026 that it entered a Securities Purchase Agreement for a registered direct offering of 7,519,351 shares of common stock at $0.325 per share (gross proceeds ≈ $2.4M) and a concurrent private placement of warrants. The private placement includes Common Warrants to purchase up to 15,038,702 shares at a $0.325 exercise price (becoming exercisable upon stockholder approval of the underlying issuances and expiring five years after that date). The Company expects the Offerings to close on or about May 21, 2026 and anticipates having at least $6.0 million in stockholders’ equity upon closing.

Key Details

• Registered offering: 7,519,351 shares at $0.325 per share; gross proceeds ≈ $2.4M (before expenses).
• Concurrent private placement: Common Warrants for up to 15,038,702 shares at $0.325 exercise; potential additional cash proceeds of ≈ $4.9M if all warrants are exercised for cash. Warrants can be exercised cashless if resale registration is not available.
• Placement agent: Ladenburg Thalmann & Co. Inc.; fees = 8.0% cash fee + 0.75% management fee of gross proceeds, plus expense reimbursement. Placement Agent Warrants: 451,161 warrants (≈6% of registered shares) with $0.40625 exercise price, expiring five years from the offering commencement.
• Registration commitments: Company agreed to file an S-1 to register the resale of the Common Warrants and underlying shares by June 8, 2026 and to use commercially reasonable efforts to have it effective within 60 days (90 days if SEC full review).

Why It Matters
This transaction provides near-term capital (≈$2.4M) to support AIM ImmunoTech’s operations and improves reported stockholders’ equity, but also introduces potential dilution from the issued warrants and placement-agent warrants. The Company could receive up to ≈$4.9M more if the private warrants are exercised for cash, though exercise is contingent on stockholder approval timing and holder decisions. Placement agent fees and issued warrants represent cash and equity costs related to raising the funds. Investors should note the registration commitment (and cashless-exercise provision) which affects when warrant holders can sell shares and whether exercises will generate cash to the company.